莫克雌醇
外觀
臨床資料 | |
---|---|
商品名 | Surestryl |
其他名稱 | R-2858, RU-2858, NSC-118191; 11β-Methoxy-17α-ethynylestradiol; 11β-MeO-EE 11β-Methoxy-17α-ethynylestra-1,3,5(10)-triene-3,17β-diol |
懷孕分級 |
|
給藥途徑 | 口服 |
藥物類別 | Estrogen; Estrogen ether |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 33%[1] |
血漿蛋白結合率 | Minimal[1] |
藥物代謝 | Liver[2] |
生物半衰期 | 8.2 hours[1] |
識別資訊 | |
| |
CAS號 | 34816-55-2 |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C21H26O3 |
摩爾質量 | 326.44 g·mol−1 |
3D模型(JSmol) | |
| |
|
莫克雌醇(英語:Moxestrol)是一種雌激素類藥物,商品名Surestryl,化學名為11β-甲氧基乙炔雌二醇,與RU-16117是11β-差向異構體,用於治療更年期綜合症和月經失調,在歐洲有上市銷售[3][4][2][5][6]。
參考資料
[編輯]- ^ 1.0 1.1 1.2 Salmon, J.; Coussediere, D.; Cousty, C.; Raynaud, J.P. Pharmacokinetics and metabolism of moxestrol in animals—rat, dog and monkey. Journal of Steroid Biochemistry. 1983, 19 (2): 1223–1234. ISSN 0022-4731. PMID 6887930. doi:10.1016/0022-4731(83)90421-1.
- ^ 2.0 2.1 Jonathan J. Li; Satyabrata Nandi; Sara A. Li. Hormonal Carcinogenesis: Proceedings of the First International Symposium. Springer Science & Business Media. 6 December 2012: 184– [2021-11-30]. ISBN 978-1-4613-9208-8. (原始內容存檔於2021-11-30).
- ^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 841– [2021-11-30]. ISBN 978-1-4757-2085-3. (原始內容存檔於2021-11-30).
- ^ Dr. Ian Morton; I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 31 October 1999: 186– [2021-11-30]. ISBN 978-0-7514-0499-9. (原始內容存檔於2021-11-30).
- ^ Adrain D. Nunn. Radiopharmaceuticals: Chemistry and Pharmacology. CRC Press. 19 June 1992: 342– [2021-11-30]. ISBN 978-0-8247-8624-3. (原始內容存檔於2021-11-30).
- ^ William Martindale; Royal Pharmaceutical Society of Great Britain. Dept. of Pharmaceutical Sciences. The Extra Pharmacopoeia. Pharmaceutical Press. 1993: 1188 [2021-11-30]. ISBN 978-0-85369-300-0. (原始內容存檔於2021-11-30).
Moxestrol is a synthetic oestrogen with actions and uses similar to thosre described for the oestrogens in general. Moxestrol is reponed to have a prolonged duration of action. It has been given by mouth in the treatment of menopausal, postmenopausal, and menstrual symptoms. Dose have ranged from 50 to 100 µg weekly for long-term therapy to 25 to 250 µg daily for short-term use.